Published in Am J Cardiol on August 01, 2004
Prognostic value of late gadolinium enhancement in hypertensive patients with known or suspected coronary artery disease. Int J Cardiovasc Imaging (2010) 0.86
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care (2011) 0.83
The ECG vertigo in diabetes and cardiac autonomic neuropathy. Exp Diabetes Res (2011) 0.81
Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2016) 0.80
Vulnerable blood in high risk vascular patients: study design and methods. Contemp Clin Trials (2014) 0.79
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med (2006) 20.27
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 18.36
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis (2008) 15.04
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis (2003) 15.00
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (2008) 11.61
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem (2005) 8.93
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol (2004) 8.21
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med (2013) 7.98
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis (2007) 7.86
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis (2002) 7.03
Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med (2007) 6.97
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int (2011) 6.01
Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol (2007) 6.00
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med (2005) 5.45
The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med (2002) 5.33
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis (2007) 5.06
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. N Engl J Med (2015) 5.03
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis (2009) 4.30
A predictive model for progression of chronic kidney disease to kidney failure. JAMA (2011) 4.22
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis (2010) 3.87
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol (2010) 3.85
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med (2008) 3.72
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis (2007) 3.53
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol (2003) 3.48
Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl (2004) 3.46
Chronic kidney disease is common: what do we do next? Nephrol Dial Transplant (2008) 3.41
Controversies in ventricular remodelling. Lancet (2006) 3.39
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis (2008) 3.34
Heart failure. Lancet (2005) 3.33
Evolving importance of kidney disease: from subspecialty to global health burden. Lancet (2013) 3.30